<DOC>
	<DOCNO>NCT00775073</DOCNO>
	<brief_summary>This prospective open label clinical trial patient advance metastatic liver cancer assess clinical biological activity RAD001 ( Everolimus ) conjunction Bevazicumab ( Avastin ) . Approximately 36 patient enrol .</brief_summary>
	<brief_title>Antiangiogenic Treatment Hepatocellular Cancer With Bevacizumab RAD001</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Age &gt; 18 year Patients nonresectable locally advanced metastatic hepatocellular cancer BCLC stage B C. BCLC stage A occasionally include provided treatment option unavailable Measurable disease : At least one measurable lesion ( long diameter ≥20 mm conventional CT MRI scan ; ≥ 10 mm spiral CT ) accord RECIST criterion previously locally treat irradiation , surgery , ethanol injection , radiofrequency ablation transarterial chemoembolisation Confirmation HCC disease histology ( precede liver resection fine needle biopsy within last 12 month ) ; Liver Function : Child A B Tumor extent : CLIP Score ≤ 3 ECOG Performance Status 02 ( =KarnofskyIndex ≥ 60 % ) Patient receive prior systemic treatment ( possible exception : sorafenib maximum 3 month , last dose receive least 28 day study inclusion ) Patient major surgery , local ablative treatment ( RFA , PEI ) , transarterial chemoembolisation therapy within 4 week prior randomisation Presence secondary malignancy either time screen past 5 year : An exception rule make patient treated curative intention within last 3 year without evidence recurrence malignancy . History presence central nervous system ( CNS ) disease ( i.e. , primary brain tumor , malignant seizure , CNS metastases carcinomatous meningitis ) mental illness . Clinically serious infection uncontrolled infection ( include HIV infection ) , increase risk acquisition opportunistic infection Chronic treatment systemic steroid another immunosuppressive agent Inadequate organ function , characterise : cholestasis elevate level bilirubin and/or alkaline phosphatase &gt; 3x UNL ( improve biliary drainage necessary ) and/or elevate transaminase ( ALAT/ASAT ) ≥ 5 x UNL , hypoalbuminemia &lt; 2.5 g/dl , renal impairment ( serum creatinine &lt; 1.5 x UNL ) , inadequate Hematology : Platelets &lt; 75.000 , ANC &lt; 1500 , hemoglobin &lt; 9.0 mg/dl , inadequate coagulation status , namely INR &gt; 2 Quick &lt; 50 % , aPTT &gt; 50 sec absence drug interfere coagulation warfarin , phenprocoumon , NMH UFH . Fasting serum cholesterol ≤300 mg/dL OR 7.75 mmol/L AND fast triglyceride ≤ 2.5 x ULN , patient severe refractory therapyresistant hyperlipidemia Women pregnant breast feeding , intended pregnancy , woman unable conceive unwilling practice effective method birth control Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption RAD001 control adequate medical treatment ( e.g . uncontrolled nausea , vomit , diarrhoea might result malabsorption , know malabsorption syndrome , bowel obstruction , inability swallow capsules/tablets ) Exclusion Criteria derive special situation : Mixed tumor HCC cholangiocarcinoma fibrolamellar HCC type Patients complication liver cirrhosis recent spontaneous bacterial infection ascites , hepatic encephalopathy &gt; grade 2 last 2 week adequately control hepatorenal syndrome respond conservative treatment within 2 week Patients active gastrointestinal bleeding last 2 week Patients without screen EGD last 2 week Patients nonbleeding gastroesophageal varix grade I° red colour sign grade ≥ II° EGD undergo prophylactic ligation sclerosing treatment least one week first dose study medication take . Patients unhealed gastrointestinal ulceration wound Patients history one following : bowel perforation , colon diverticulitis Any relevant finding screen colonoscopy History thromboembolic event ( except portal vein infiltration and/or thrombosis ) Allergic reaction intolerance previous drug exposure RAD001 bevacizumab ; receive study medication within last 3 year randomisation Allergy intolerance CHOcell product recombinant human humanise antibody Patients increase risk development lymphoma malignant disease , especially concern skin Patients rare hereditary disorder like galactose intolerance , lactase deficiency glucosegalactose malabsorption</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Liver cancer</keyword>
	<keyword>HCC</keyword>
</DOC>